A global healthcare company, Johnson & Johnson Innovative Medicines (J\&J), is preparing to close its operations in Nigeria. The decision highlights the growing challenges facing multinational companies in Africa’s largest economy.
Sources told the Commerce and Industry Correspondents Association of Nigeria (CICAN) that the exit is linked to Nigeria’s tough economic climate. The country has been struggling with high inflation, shortage of foreign exchange, rising production costs, and unstable government policies.
The source, who did not want to be named, said J\&J has been a major supplier of important medicines and health products in Nigeria. But the difficult business environment has now made it impossible for the company to continue.
“In the past year, they reduced their workforce by about 80%, leaving only around 20% of their staff,” the source revealed. “Back in 2022, the Consumer Healthcare arm of the company had already withdrawn quietly from Nigeria.”
Observers say this is more than just one company leaving. If a leading healthcare giant like Johnson & Johnson cannot cope in Nigeria, it raises serious concerns for other global investors looking at the country.
The exit of J\&J is expected to create a big gap in the health sector. Nigerians may now face limited access to vital medicines, especially in areas like cancer treatment (oncology), immune-related diseases, and mental health care.
